Comparison of Cardiovascular Outcomes Between Dapagliflozin and Empagliflozin in Patients With Type 2 Diabetes: A Meta-Analysis.

Autor:	Memon RA; Internal Medicine, Abington Memorial Hospital, Abington, USA., Akbariromani H; Medical School, Islamic Azad University, Tehran, IRN., Vohra RR; Internal Medicine, Dow Medical College, Karachi, PAK., Kundi H; Medical School, Fazaia Medical College, Karachi, PAK., Saleem RF; Internal Medicine, Akhtar Saeed Medical and Dental College, Lahore, PAK., Ghaffari MA; Anatomy, Akhtar Saeed Medical and Dental College, Lahore, PAK., Haas D; Cardiovascular Medicine, Abington Memorial Hospital, Abington, USA., Khan A; Critical Care Medicine, United Medical and Dental College, Karachi, PAK.
Jazyk:	angličtina
Zdroj:	Cureus [Cureus] 2022 Jul 26; Vol. 14 (7), pp. e27277. Date of Electronic Publication: 2022 Jul 26 (Print Publication: 2022).
DOI:	10.7759/cureus.27277
Abstrakt:	Sodium-glucose cotransporter-2 (SGLT2) inhibitors are oral diabetes medications that enhance the excretion of glucose by preventing the renal proximal tubules from reabsorbing glucose, which lowers glucose levels in plasma. Currently, studies have shown that SGLT2 inhibitors have beneficial impacts on cardiovascular outcomes, but their effect varies between the individual SGLT2 inhibitors. Thus, the current meta-analysis was conducted to compare the efficacy of dapagliflozin and empagliflozin in preventing cardiovascular events in patients with type 2 diabetes. The current meta-analysis was conducted using the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) reporting guidelines. A search of studies comparing cardiovascular events between dapagliflozin and empagliflozin in patients with type 2 diabetes published up to 1 July 2022 was done by two reviewers independently on PubMed, Embase and Cumulated Index to Nursing and Allied Health Literature (CINAHIL). The pre-specified primary endpoints were cardiovascular death, stroke, myocardial infarction and heart failure. Overall four studies were included in this meta-analysis. No significant difference was found in the incidence of myocardial infarction (risk ratio (RR)=0.81, 95% confidence interval (CI): 0.60-1.09), heart failure (RR=0.76, 95% CI: 0.56-1.04), cardiovascular mortality (RR=0.46, 95% CI: 0.18-1.20) and stroke (RR=1.07, 95% CI: 0.84-1.38) between dapagliflozin and empagliflozin. Results have shown that the risk of developing stroke, heart failure, myocardial infarction and cardiovascular death were not significantly different in the two groups. Competing Interests: The authors have declared that no competing interests exist. (Copyright © 2022, Memon et al.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu